Skip to content

US · FBIOP · BIOTECHNOLOGY

Fortress Biotech, Inc. (FBIOP) intrinsic value and stock valuation

$13.60as of 2026-11-21 · Mkt cap 150.99M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Fortress Biotech, Inc. DCF and intrinsic value

InvestorsCraft values FBIOP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FBIOP’s statements →

Fortress Biotech, Inc. Graham Number

Graham Number: $3.50d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Bay Harbor Islands, FL 33154 fortressbiotech.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$63.3M+6.8% 5y CAGRd
20112025
Net income
$6.82M
20112025
Free cash flow
-$-65.78M
20112025
Total equity
$62.2M-20.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$63.3M$57.7M$84.5M$75.7M$68.8M
Operating income-$-70.22M-$-110.38M-$-142.34M-$-203.56M-$-188.54M
Net income$6.82M-$-46M-$-60.64M-$-86.58M-$-64.7M
EPSd$24.4K-$-2.21M-$-7.48M-$-14.63M-$-11.87M
Operating cash flow-$-65.78M-$-80.19M-$-128.22M-$-179.4M-$-116.54M
Capital expenditure$0.00-$-15M-$-8.1M-$-3.06M-$-16.35M
Free cash flow-$-65.78M-$-95.19M-$-136.32M-$-182.46M-$-132.89M
Total assets$185.6M$144.2M$167.5M$294.3M$396.5M
Total debt$74.3M$76M$84.7M$127.3M$75M
Net debt-$-5.08M$18.7M$3.73M-$-50.92M-$-230.77M
Total equity$62.2M-$-1.64M$1.59M$50M$225.9M
Cash and short-term investments$79.4M$57.3M$80.9M$178.3M$305.7M
Income statement
20252024202320222021
Revenue$63.3M$57.7M$84.5M$75.7M$68.8M
Cost of revenue$20.9M$20.9M$22.9M$30.8M$32.1M
Gross profit$42.3M$36.8M$61.6M$45M$36.7M
Research and development expenses$11.9M$56.9M$106.1M$134.9M$128.9M
Selling, general and administrative expenses$96.4M$87.7M$91M$113.7M$86.8M
Other expenses$4.26M$2.56M$6.91M$0.00$9.54M
Operating expenses$112.6M$147.2M$204M$248.5M$225.3M
Cost and expenses$133.5M$168.1M$226.9M$279.3M$257.3M
Interest income$2.48M$2.68M$3M$1.4M$650K
Interest expense$8.71M$9.93M$12.5M$13.6M$15.3M
Depreciation and amortization$4.66M$4.46M$6M$9.35M$6.79M
Ebitda-$-20.16M-$-104.49M-$-135.72M-$-193.69M-$-146.17M
Operating income-$-70.22M-$-110.38M-$-142.34M-$-203.56M-$-188.54M
Total other income/expenses, net$36.7M-$-10.16M-$-11.29M-$-9.9M$24.2M
Income before tax-$-33.53M-$-120.54M-$-153.63M-$-213.46M-$-164.35M
Income tax expense-$-620K$310K$520K$450K$470K
Net income$6.82M-$-46M-$-60.64M-$-86.58M-$-64.7M
Weighted average shares outstanding$27.9M$20.8M$8.11M$5.92M$5.45M
Weighted average diluted shares outstanding$279M$20.8M$8.11M$5.92M$5.45M
Balance sheet
20252024202320222021
Cash and short-term investments$79.4M$57.3M$80.9M$178.3M$305.7M
Net receivables$29.9M$10.4M$15.4M$28.4M$23.8M
Inventory$9.62M$14.4M$10.2M$14.2M$9.86M
Total current assets$123.8M$90.4M$117M$230.4M$346.5M
Property, plant and equipment, net$14.8M$17.1M$23.5M$33M$34.1M
Goodwill and intangible assets$27.6M$31.9M$20.3M$27.2M$12.6M
Long-term investments$17.7M$1.55M$2.44M$2.69M$2.22M
Total non-current assets$61.7M$53.9M$50.5M$63.9M$50M
Total assets$185.6M$144.2M$167.5M$294.3M$396.5M
Accounts payable$14.2M$31.6M$34.8M$57.2M$47.4M
Short-term debt$2.13M$3.25M$5.52M$12.6M$7.43M
Deferred revenue$0.00$0.00$0.00$730K$2.61M
Total current liabilities$49.7M$71.4M$84.9M$127.7M$101M
Long-term debt$72.2M$72.7M$79.1M$114.7M$67.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$73.6M$74.5M$81M$116.6M$69.6M
Capital lease obligations$14.8M$17.4M$20.8M$24M$23.1M
Total liabilities$123.4M$145.9M$165.9M$244.3M$170.6M
Common stock$30K$30K$10K$110K$100K
Retained earnings-$-734.05M-$-740.87M-$-694.87M-$-634.23M-$-547.46M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$62.2M-$-1.64M$1.59M$50M$225.9M
Total investments$17.7M$1.55M$2.44M$2.69M$2.22M
Total debt$74.3M$76M$84.7M$127.3M$75M
Net debt-$-5.08M$18.7M$3.73M-$-50.92M-$-230.77M
Cash flow statement
20252024202320222021
Net income-$-32.91M-$-120.86M-$-154.15M-$-213.91M-$-164.83M
Depreciation and amortization$4.66M$4.46M$6M$9.35M$6.79M
Stock-based compensation$28.7M$32.6M$17M$23M$19.5M
Change in working capital-$-25.1M-$-8.13M-$-12.52M-$-710K$36.4M
Accounts receivable-$-19.33M$4.47M$12.5M-$-4.84M$830K
Inventory$4.81M-$-4.22M$3.95M$1.74M-$-8.46M
Accounts payable-$-7.97M-$-6.39M-$-24.38M$8.35M$43.3M
Net cash provided by operating activities-$-65.78M-$-80.19M-$-128.22M-$-179.4M-$-116.54M
Investments in property, plant and equipment$0.00-$-15M-$-60K-$-2.71M-$-4.57M
Acquisitions, net$8.96M$0.00$0.00-$-20M$56.9M
Net cash used for investing activities$10.1M-$-15M-$-2.1M-$-22.93M$40.5M
Common stock issued$84.6M$82.8M$80.4M$40.3M$155.3M
Common stock repurchased-$-270K$0.00$0.00-$-1.11M$0.00
Dividends paid-$-660K-$-4.71M-$-8.77M-$-8.78M-$-8.78M
Net cash used for financing activities$77.4M$70.6M$32.7M$75.3M$149M
Net change in cash$21.8M-$-24.55M-$-97.59M-$-127.01M$73M
Cash at end of period$80.6M$58.8M$83.4M$181M$308M
Operating cash flow-$-65.78M-$-80.19M-$-128.22M-$-179.4M-$-116.54M
Capital expenditure$0.00-$-15M-$-8.1M-$-3.06M-$-16.35M
Free cash flow-$-65.78M-$-95.19M-$-136.32M-$-182.46M-$-132.89M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Fortress Biotech, Inc.

        Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

        CEO
        Lindsay A. Rosenwald
        Employees
        78
        Beta
        1.21

        Explore

        Frequently asked questions

        What is the intrinsic value of Fortress Biotech, Inc. (FBIOP)?

        InvestorsCraft does not currently publish an intrinsic value for FBIOP. How the IC value is calculated.

        Is FBIOP undervalued?

        InvestorsCraft does not publish an undervaluation signal for FBIOP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.